Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis

Tuberculosis Trials Consortium

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Abstract Summary Rationale Biomarkers for monitoring response to anti-tuberculosis treatment are needed. We explored immune markers previously published as having predictive capability for 8 week culture status in 39 adults enrolled in a clinical trial in Kampala, Uganda. Methods We consecutively selected 20 HIV-negative pulmonary TB subjects with positive cultures, and 19 subjects with negative cultures at the end of intensive phase therapy. At baseline and after 8 weeks, serum was assayed for nine cytokines and soluble cytokine receptors using multiplexed platforms or ELISA. We evaluated their association with week 8 culture status first using single-variable logistic models, then using cross-validated estimates of the C-statistic, a measure of discrimination, of candidate models including 2 or 3 analytes in addition to age. Results All but one analyte decreased from baseline to week 8 (all p < 0.01). Individual biomarkers were not associated with 8 week culture status. Logistic models including increasing age, higher baseline soluble tumor necrosis factor receptor alpha 1 (sTNF-R1), and higher week 8 C-reactive protein (CRP) concentration classified subjects by culture status with up to 85% accuracy and acceptable discrimination (cross-validated C-statistic 0.76) and calibration (Hosmer-Lemeshow P > 0.2). Conclusion Exploratory post-hoc models including sTNF-R1, CRP, and age, classified 8 week culture status with promising accuracy.

Original languageEnglish (US)
Article number1332
Pages (from-to)415-420
Number of pages6
Issue number4
StatePublished - Jul 1 2015


  • Biomarkers
  • Pulmonary
  • Treatment response
  • Tuberculosis

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis'. Together they form a unique fingerprint.

Cite this